The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

NAA16  -  N(alpha)-acetyltransferase 16, NatA...

Homo sapiens

Synonyms: FLJ22054, MGC40612, N-alpha-acetyltransferase 16, NatA auxiliary subunit, NARG1-like protein, NARG1L, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NARG1L

  • The N-acetyltransferase-2 gene (NAT-2) has been associated with Parkinson's disease [1].
  • The relationship between endometriosis and polymorphisms in the N-acetyl transferase 2 (NAT 2) gene was investigated in a UK population, as this gene has been previously implicated in the aetiology of the disease [2].
  • The observed heterogeneity of NAT1 and NAT2 mRNA expression between human tissue types may be of significance in assessing their contribution to known organ-specific toxicities of various arylamine drugs and carcinogens [3].

Psychiatry related information on NARG1L

  • NAT isozymes are encoded at 2 loci; one encodes NAT1, formerly known as the monomorphic form of the enzyme, while the other encodes the polymorphic NAT2, which is responsible for individual differences in the ability to acetylate certain compounds [3].

High impact information on NARG1L

  • We show here that human NAT1 but not human NAT2 is expressed in pre-implantation embryos at the blastocyst stage and show that NAT1 is also expressed in early human placenta at the earliest available stage, 5.5 weeks [4].
  • However, addition of the NAT2-selective substrates sulfamethazine, dapsone, or procainamide did not alter NAT1 activity [5].
  • It is evident from the amount of discordance between caffeine phenotype and dapsone phenotype or genotype that caution should be exercised in the use of caffeine as a probe for NAT2 in acutely ill patients [6].
  • Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2 [7].
  • This lack of information is in contrast to the many studies of ethnic differences in NAT2* alleles and phenotypes [8].

Biological context of NARG1L

  • The NAT2 genotype distribution was 45:55 slow:rapid [6].
  • Polymerase chain reaction amplification and restriction fragment length polymorphism analysis served to distinguish between the 26 known NAT2 alleles and the 21 most common NAT1 alleles [6].
  • Geographic and ethnic variation in the frequency of NAT2 genotypes associated with fast or intermediate acetylation has been observed [9].
  • The two expressed genes coding for N-acetyltransferase (NAT) activity, NAT1 and NAT2, are located on chromosome 8 at 8p21.3-23.1 and are polymorphic [9].
  • Single base-pair substitutions in NAT2 tend to occur in combination with other substitutions within the gene [9].

Anatomical context of NARG1L


Associations of NARG1L with chemical compounds


Analytical, diagnostic and therapeutic context of NARG1L


  1. N-acetyltransferase-2 polymorphism in Parkinson's disease: the Rotterdam study. Harhangi, B.S., Oostra, B.A., Heutink, P., van Duijn, C.M., Hofman, A., Breteler, M.M. J. Neurol. Neurosurg. Psychiatr. (1999) [Pubmed]
  2. Association between endometriosis and N-acetyl transferase 2 polymorphisms in a UK population. Nakago, S., Hadfield, R.M., Zondervan, K.T., Mardon, H., Manek, S., Weeks, D.E., Barlow, D., Kennedy, S. Mol. Hum. Reprod. (2001) [Pubmed]
  3. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Windmill, K.F., Gaedigk, A., Hall, P.M., Samaratunga, H., Grant, D.M., McManus, M.E. Toxicol. Sci. (2000) [Pubmed]
  4. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Smelt, V.A., Upton, A., Adjaye, J., Payton, M.A., Boukouvala, S., Johnson, N., Mardon, H.J., Sim, E. Hum. Mol. Genet. (2000) [Pubmed]
  5. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Butcher, N.J., Ilett, K.F., Minchin, R.F. Mol. Pharmacol. (2000) [Pubmed]
  6. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. O'Neil, W.M., Drobitch, R.K., MacArthur, R.D., Farrough, M.J., Doll, M.A., Fretland, A.J., Hein, D.W., Crane, L.R., Svensson, C.K. Pharmacogenetics (2000) [Pubmed]
  7. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Goodfellow, G.H., Dupret, J.M., Grant, D.M. Biochem. J. (2000) [Pubmed]
  8. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Dhaini, H.R., Levy, G.N. Pharmacogenetics (2000) [Pubmed]
  9. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Brockton, N., Little, J., Sharp, L., Cotton, S.C. Am. J. Epidemiol. (2000) [Pubmed]
  10. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. Filiadis, I.F., Georgiou, I., Alamanos, Y., Kranas, V., Giannakopoulos, X., Lolis, D. J. Urol. (1999) [Pubmed]
  11. N-acetyltransferase 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Westphal, G.A., Reich, K., Schulz, T.G., Neumann, C., Hallier, E., Schnuch, A. Br. J. Dermatol. (2000) [Pubmed]
WikiGenes - Universities